Stay updated with breaking news from Mako Shoulder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Needham analyst upgrades SYK to Buy, expects new products & M&A to drive upside in revenue & EPS. Strong backlog & growth potential make shares attractive.
Needham analysts upgraded Stryker from "Neutral" to "Buy" ahead of potentially significant improvements in the coming years.
From pulsed field ablation to diabetes, surgical robotics, and plenty more, a number of medical device launches sit on the horizon in 2024.
Stryker is using AAOS 2024 to showcase new joint replacement technology and updates to its Mako surgical robotic platform.
All three of these companies have seen double-digit increases in their share prices this year.